With so many weight loss medications on the market, it's easy to feel overwhelmed by the options. From brand-name heavy ...
The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.
With Eli Lilly's diabetes and obesity products Mounjaro and Zepbound booming in popularity, the drugmaker finds itself in a ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
The Commonwealth Fund 2024 Biennial Health Insurance Survey found that 8 percent of Americans had no health insurance in 2023. It also found that 3 in 5 underinsured adults said they avoided care ...
A new national survey shows that, despite intense marketing, most Americans do not want the new weight-loss injectables, such ...
One particular healthcare stock has shown its ability to soar on good news -- and it's had plenty of it. This year the ...
For the past year, there has been a huge buzz about the so-called "weight loss injection". This is supposed to help people ...
The firm backed the insurance broker's creation in 2011, sold a majority stake in 2015 and reacquired it in 2019. Mao Geping Cosmetics shares jumped in their trading debut in Hong Kong after an ...
Novo Nordisk got European approval to move forward with its planned buyout of U.S.-based drug manufacturer Catalent, which produces much of its popular obesity drug Wegovy. That leaves the U.S.